Sign in Create account

Ishita Drugs & Industries Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524400
₹74.00
▲ 2.00 (2.78%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
52/100
Moderate
Valuation
48/100
Fairly Valued
Momentum
85/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹22 Cr
PE (TTM)
31.4
Industry median 36.1 (152 companies)
Price to Book
1.9
PEG (TTM)
-1.6
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-16.8
Free Cash Flow
₹2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-23.76%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
7.37%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-21.67%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-23.84%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-41.77%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
9.65
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
25.46
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
7.31%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
9.69%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.33%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.24%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
9.81%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
7.88%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (7.9%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

4 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
2.8%
Low 72.0000 · High 74.0000
1W return
2.2%
Low 72.0000 · High 75.9900
1M return
1.8%
Low 70.0000 · High 75.9900
52W return
-16.8%
Low 70.0000 · High 78.6900
Lifetime High ₹90.5600 (Feb. 2, 2024)
Lifetime Low ₹5.1600 (Nov. 20, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
73.2
10D
72.9
20D
72.7
50D
71.7
100D
71.0
200D
71.4

Delivery and volume

Day avg. delivery
99.9%
Week avg. delivery
98.7%
Month avg. delivery
99.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

73.33
Pivot
First resistance74.67
Second resistance75.33
Third resistance76.67
First support72.67
Second support71.33
Third support70.67
Day RSI53.9
Day MFI67.5
Day MACD0.31
Day MACD signal0.29

Beta

1M0.92
3M1.20
1Y1.20
3Y0.53

Price change analysis

↑ 1.8%
Over 1 Month
LowHigh
70.0075.99
↓ -16.8%
Over 3 Months
LowHigh
70.0078.69
↓ -16.8%
Over 6 Months
LowHigh
70.0078.69
↓ -16.8%
Over 1 Year
LowHigh
70.0078.69
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 31.4 (own history: 26.2–37.7)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹3 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.7700

Ranks #163 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter50.04%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 50.04% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 146 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
15 Sep 2025 BHUPESHBHAI VAHLABHAI PATEL Bulk Sell 24,997 77.0000 BSE
15 Sep 2025 ISHITA PHARMACEUTICALS Bulk Buy 25,334 76.9900 BSE
11 Sep 2025 BHUPESHBHAI VAHLABHAI PATEL Bulk Sell 20,200 75.3400 BSE
11 Sep 2025 USHA JAWAHARLAL KALRO Bulk Buy 22,689 75.1900 BSE
11 Sep 2025 USHA JAWAHARLAL KALRO Bulk Sell 22,689 77.5800 BSE
25 Nov 2024 RAJAN MALHOTRA Bulk Buy 18,421 83.1200 BSE
25 Nov 2024 PUNEET MITTAL HUF Bulk Sell 25,714 89.1500 BSE
25 Nov 2024 PUNEET MITTAL HUF Bulk Buy 25,714 88.2800 BSE
17 Sep 2024 BHUPESHBHAI VAHLABHAI PATEL Bulk Sell 35,000 80.0000 BSE
17 Sep 2024 VIKKRAMM CHANDIRRAMANI Bulk Buy 39,934 79.8900 BSE

All bulk and block deals →

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
2 Oct 2026 AGM/EGM Ishita Drugs & Industries Ltd - 524400 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
2 Oct 2026 Company Update Ishita Drugs & Industries Ltd - 524400 - Announcement under Regulation 30 (LODR)-Change in Management
2 Oct 2026 Company Update Ishita Drugs & Industries Ltd - 524400 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
30 Sep 2026 AGM/EGM Ishita Drugs & Industries Ltd - 524400 - Shareholder Meeting / Postal Ballot-Outcome of AGM
18 Sep 2026 Board Meeting Ishita Drugs & Industries Ltd - 524400 - Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (25.5x)

Weaknesses

  • Low Return on Equity (7.9%)
  • Declining revenue YoY (-41.8%)
  • Declining profit YoY (-23.8%)

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Ishita Drugs & Industries Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.